Literature DB >> 29184475

Management of the Complete Clinical Response.

Angelita Habr-Gama1,2, Guilherme Pagin São Julião1, Bruna Borba Vailati1, Ivana Castro1, Debora Raffaele1.   

Abstract

Organ preservation is considered in the management of selected patients with rectal cancer. Complete clinical response observed after neoadjuvant chemoradiation for rectal cancer is one of these cases. Patients who present complete clinical response are candidates to the watch-and-wait approach, when radical surgery is not immediately performed and is offered only to patients in the event of a local relapse. These patients are included in a strict follow-up, and up of 70% of them will never be operated during the follow-up. This strategy is associated with similar oncological outcomes as patients operated on, and the advantage of avoiding the morbidity associated to the radical operation. In this article we will discuss in detail the best candidates for this approach, the protocol itself, and the long-term outcomes.

Entities:  

Keywords:  complete response; neoadjuvant therapy; rectal cancer; watch-and-wait

Year:  2017        PMID: 29184475      PMCID: PMC5703663          DOI: 10.1055/s-0037-1606116

Source DB:  PubMed          Journal:  Clin Colon Rectal Surg        ISSN: 1530-9681


  65 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Nonoperative management of rectal cancer after chemoradiation opposed to resection after complete clinical response. A comparative study.

Authors:  R O C Araujo; M Valadão; D Borges; E Linhares; J P de Jesus; C G Ferreira; A P Victorino; F M Vieira; R Albagli
Journal:  Eur J Surg Oncol       Date:  2015-08-29       Impact factor: 4.424

3.  Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.

Authors:  Julio Garcia-Aguilar; Oliver S Chow; David D Smith; Jorge E Marcet; Peter A Cataldo; Madhulika G Varma; Anjali S Kumar; Samuel Oommen; Theodore Coutsoftides; Steven R Hunt; Michael J Stamos; Charles A Ternent; Daniel O Herzig; Alessandro Fichera; Blase N Polite; David W Dietz; Sujata Patil; Karin Avila
Journal:  Lancet Oncol       Date:  2015-07-14       Impact factor: 41.316

4.  Surveillance after neoadjuvant therapy in advanced rectal cancer with complete clinical response can have comparable outcomes to total mesorectal excision.

Authors:  Radhika K Smith; Robert D Fry; Najjia N Mahmoud; E Carter Paulson
Journal:  Int J Colorectal Dis       Date:  2015-03-19       Impact factor: 2.571

5.  Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization.

Authors:  Angelita Habr-Gama; Rodrigo O Perez; Gregory Wynn; John Marks; Hermann Kessler; Joaquim Gama-Rodrigues
Journal:  Dis Colon Rectum       Date:  2010-12       Impact factor: 4.585

6.  Prediction of response to preoperative chemoradiotherapy in rectal cancer by using reverse transcriptase polymerase chain reaction analysis of four genes.

Authors:  Toshiaki Watanabe; Takashi Kobunai; Takashi Akiyoshi; Keiji Matsuda; Soichiro Ishihara; Keijiro Nozawa
Journal:  Dis Colon Rectum       Date:  2014-01       Impact factor: 4.585

7.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

8.  Pathologic Complete Response in Rectal Cancer: Can We Detect It? Lessons Learned From a Proposed Randomized Trial of Watch-and-Wait Treatment of Rectal Cancer.

Authors:  Sergio Carlos Nahas; Caio Sergio Rizkallah Nahas; Carlos Frederico Sparapan Marques; Ulysses Ribeiro; Guilherme Cutait Cotti; Antonio Rocco Imperiale; Fernanda Cunha Capareli; Andre Tsin Chih Chen; Paulo M Hoff; Ivan Cecconello
Journal:  Dis Colon Rectum       Date:  2016-04       Impact factor: 4.585

9.  Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer.

Authors:  Matthew F Kalady; Luiz Felipe de Campos-Lobato; Luca Stocchi; Daniel P Geisler; David Dietz; Ian C Lavery; Victor W Fazio
Journal:  Ann Surg       Date:  2009-10       Impact factor: 12.969

10.  Short-course preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study.

Authors:  Calin Radu; Ake Berglund; Lars Påhlman; Bengt Glimelius
Journal:  Radiother Oncol       Date:  2008-02-21       Impact factor: 6.280

View more
  6 in total

Review 1.  Critical and Challenging Issues in the Surgical Management of Low-Lying Rectal Cancer.

Authors:  Aeris Jane D Nacion; Youn Young Park; Seung Yoon Yang; Nam Kyu Kim
Journal:  Yonsei Med J       Date:  2018-08       Impact factor: 2.759

Review 2.  Meta-analysis of the prognostic value of CpG island methylator phenotype in rectal cancer.

Authors:  R F Kokelaar; H Jones; J Beynon; M E Evans; D A Harris
Journal:  Int J Colorectal Dis       Date:  2018-06-20       Impact factor: 2.571

3.  A Non-Operative Approach to Rectal Cancer after Chemo-Radiotherapy: Case Series and Review.

Authors:  Abeer Arain; Priyank Patel
Journal:  Kans J Med       Date:  2019-02-26

4.  Neoadjuvant chemoradiation for locally advanced rectal cancer: a systematic review of the literature with network meta-analysis.

Authors:  Min Chen; Liang-Zhou Chen; Lin Xu; Jin-Song Zhang; Xue Song
Journal:  Cancer Manag Res       Date:  2019-01-15       Impact factor: 3.989

5.  Delta radiomics for rectal cancer response prediction with hybrid 0.35 T magnetic resonance-guided radiotherapy (MRgRT): a hypothesis-generating study for an innovative personalized medicine approach.

Authors:  Luca Boldrini; Davide Cusumano; Giuditta Chiloiro; Calogero Casà; Carlotta Masciocchi; Jacopo Lenkowicz; Francesco Cellini; Nicola Dinapoli; Luigi Azario; Stefania Teodoli; Maria Antonietta Gambacorta; Marco De Spirito; Vincenzo Valentini
Journal:  Radiol Med       Date:  2018-10-29       Impact factor: 3.469

6.  Potential of miR-21 to Predict Incomplete Response to Chemoradiotherapy in Rectal Adenocarcinoma.

Authors:  Susana Ourô; Cláudia Mourato; Sónia Velho; André Cardador; Marisa P Ferreira; Diogo Albergaria; Rui E Castro; Rui Maio; Cecília M P Rodrigues
Journal:  Front Oncol       Date:  2020-10-27       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.